<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Glaser J</submitter><funding>UT-Battelle</funding><funding>Oak Ridge National Laboratory</funding><pagination>255-265</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9003389</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>5(4)</volume><pubmed_abstract>Inhibition of the SARS-CoV-2 main protease (M&lt;sup>pro&lt;/sup>) is a major focus of drug discovery efforts against COVID-19. Here we report a hit expansion of non-covalent inhibitors of M&lt;sup>pro&lt;/sup>. Starting from a recently discovered scaffold (The COVID Moonshot Consortium. Open Science Discovery of Oral Non-Covalent SARS-CoV-2 Main Protease Inhibitor Therapeutics. bioRxiv 2020.10.29.339317) represented by an isoquinoline series, we searched a database of over a billion compounds using a cheminformatics molecular fingerprinting approach. We identified and tested 48 compounds in enzyme inhibition assays, of which 21 exhibited inhibitory activity above 50% at 20 μM. Among these, four compounds with IC&lt;sub>50&lt;/sub> values around 1 μM were found. Interestingly, despite the large search space</pubmed_abstract><journal>ACS pharmacology &amp; translational science</journal><pubmed_title>Hit Expansion of a Noncovalent SARS-CoV-2 Main Protease Inhibitor.</pubmed_title><pmcid>PMC9003389</pmcid><funding_grant_id>DE-AC05-00OR22725</funding_grant_id><funding_grant_id>LOIS 10126</funding_grant_id><pubmed_authors>Kovalevsky A</pubmed_authors><pubmed_authors>Parks JM</pubmed_authors><pubmed_authors>Smith DMA</pubmed_authors><pubmed_authors>Labbe A</pubmed_authors><pubmed_authors>Coates L</pubmed_authors><pubmed_authors>Del Galdo S</pubmed_authors><pubmed_authors>Agarwal R</pubmed_authors><pubmed_authors>Sedova A</pubmed_authors><pubmed_authors>Davidson RB</pubmed_authors><pubmed_authors>Maradzike E</pubmed_authors><pubmed_authors>Glaser J</pubmed_authors><pubmed_authors>Bykov D</pubmed_authors><pubmed_authors>Daidone I</pubmed_authors><pubmed_authors>Kneller DW</pubmed_authors><pubmed_authors>Hsu DJ</pubmed_authors><pubmed_authors>Galanie S</pubmed_authors><pubmed_authors>Tharrington A</pubmed_authors><pubmed_authors>Smith JC</pubmed_authors></additional><is_claimable>false</is_claimable><name>Hit Expansion of a Noncovalent SARS-CoV-2 Main Protease Inhibitor.</name><description>Inhibition of the SARS-CoV-2 main protease (M&lt;sup>pro&lt;/sup>) is a major focus of drug discovery efforts against COVID-19. Here we report a hit expansion of non-covalent inhibitors of M&lt;sup>pro&lt;/sup>. Starting from a recently discovered scaffold (The COVID Moonshot Consortium. Open Science Discovery of Oral Non-Covalent SARS-CoV-2 Main Protease Inhibitor Therapeutics. bioRxiv 2020.10.29.339317) represented by an isoquinoline series, we searched a database of over a billion compounds using a cheminformatics molecular fingerprinting approach. We identified and tested 48 compounds in enzyme inhibition assays, of which 21 exhibited inhibitory activity above 50% at 20 μM. Among these, four compounds with IC&lt;sub>50&lt;/sub> values around 1 μM were found. Interestingly, despite the large search space</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Apr</publication><modification>2026-05-09T17:37:21.613Z</modification><creation>2024-11-10T08:43:41.215Z</creation></dates><accession>S-EPMC9003389</accession><cross_references><pubmed>35434531</pubmed><doi>10.1021/acsptsci.2c00026</doi></cross_references></HashMap>